CONSOLIDATED AND COMBINED STATEMENTS OF CASH FLOWS (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011
Operating Activities
Net income before allocation to noncontrolling interests	$ 503		$ 436		$ 248	[1],[2]
Adjustments to reconcile net income before noncontrolling interests to net cash provided by/(used in) operating activities
Depreciation and amortization expense	209	[3]	200	[3]	205	[3]
Share-based compensation expense	43		28		19
Asset write-offs and asset impairments	15		10		78
Deferred taxes	23		(74)		65
Employee benefit plan contribution from Pfizer Inc.	2		0		0
Other non-cash adjustments	(10)		3		(1)
Other changes in assets and liabilities, net of acquisitions and divestitures and transfers with Pfizer Inc. [Abstract]
Accounts receivable	(99)		(65)		(85)
Inventories	(104)		(318)		40
Other assets	(24)		(5)		11
Accounts payable	(82)		96		(16)
Other liabilities	196		62		(15)
Other tax accounts, net	9		81		(52)
Net cash provided by operating activities	681		454		497
Investing Activities
Purchases of property, plant and equipment	(184)		(126)		(135)
Net proceeds from sales of assets	9		3		34
Acquisitions, net of cash acquired	(4)		0		(345)
Other investing activities	0		(12)		(3)
Net cash used in investing activities	(179)		(135)		(449)
Financing Activities
Allocated principal payments on long-term debt	0		0		(143)
Increase in short-term borrowings, net	16		0		0
Proceeds from issuance of long-term debt—senior notes, net of discount and fees	2,625		0		0
Consideration paid to Pfizer Inc. in connection with the Separation(a)	(2,559)	[4]	0	[4]	0	[4]
Cash dividends paid(b)	(98)	[5]	(63)	[5]	(416)	[5]
Other net financing activities with Pfizer Inc.	(184)		(15)		529
Net cash used in financing activities	(200)		(78)		(30)
Effect of exchange-rate changes on cash and cash equivalents	(9)		(3)		(2)
Net increase in cash and cash equivalents	293		238		16
Cash and cash equivalents at beginning of period	317	[6]	79		63
Cash and cash equivalents at end of period	610	[6]	317	[6]	79
Cash paid during the period for:
Income taxes	134		276		142
Interest, net of capitalized interest	60		31		37
Non-cash transactions:
Contingent purchase price consideration	3		0		0
Dividends declared, not paid	36		0		0
Zoetis Inc. senior notes transferred to Pfizer Inc. in connection with the Separation(c)	$ 992	[7]	$ 0	[7]	$ 0	[7]

[1] Includes impacts from acquisitions from the acquisition date, see Note 3. Basis of Presentation and Note 5. Acquisitions, Divestitures and Certain Investments.

[2] Includes revenue and expenses from acquisitions from the acquisition date, see Note 3. Basis of Presentation and Note 5. Acquisitions, Divestitures and Certain Investments.

[3] Certain production facilities are shared. Depreciation and amortization is allocated to the reportable operating segments based on estimates of where the benefits of the related assets are realized.

[4] Reflects the Separation transaction. Amount is net of the non-cash portion. See Note 2A. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: The Separation.

[5] For the twelve months ended December 31, 2012 and December 31, 2011, reflects payments to other non-Zoetis Pfizer Inc. entities.

[6] The consolidated balance sheet as of December 31, 2013 has been prepared under a different basis of presentation than the combined balance sheet as of December 31, 2012, which significantly impacts comparability. See Note 3. Basis of Presentation.

[7] Reflects the non-cash portion of the Separation transaction. See Note 2A. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: The Separation.